Computerized Systems for Managing Glucose Will Become Standard of Care in Hospitals, Anticipates Dr. Bruce Bode

A presentation at ATTD 2019 by renowned diabetologist and researcher, Dr. Bruce Bode, showcased superior clinical and financial outcomes with Glytec’s eGlycemic Management System^® versus usual care across multiple studies.

WALTHAM, Mass.--(BUSINESS WIRE)--In conclusion to his plenary session at the 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019), Dr. Bruce Bode delivered a call-to-action to an audience of his peers, espousing they do what is necessary to normalize glucose for all hospitalized patients (emphasis on ALL). He stressed that rates of hypoglycemia remain unacceptably high and use of sliding scale insulin continues to be prevalent despite abundant evidence denouncing it as unsafe and lacking efficacy. “Patients deserve better,” said Bode. With a clear focus on the solution to a decades-long problem of poor glucose control in hospitals, Bode described in detail the advantages of computerized decision support, highlighting data from multiple studies of Glytec’s FDA-cleared eGlycemic Management System^® (eGMS^®) that demonstrate consistently superior outcomes versus usual care, including significant reductions in hypoglycemia, 30-day readmissions and lengths of stay.

Representative Outcomes From Studies Mentioned:
Outcome	Usual Care	Glytec eGMS^®	Improvement
Average LOS Hospital-Wide^1	7.18 Days	5.51 Days	23.3% Decrease (1.67 Days)
Median LOS for DKA^2	4.5 Days	3.2 Days	28.9% Decrease (1.3 Days)
Basal-Bolus Insulin Use^3	5%	96%	1,820% Increase (91% Absolute)
30-Day Readmission Rate for CABG^4	12.71%	5.24%	58.8% Decrease (7.47% Absolute)
POC Rate Hypoglycemia <40 mg/dL^5	0.41% BGs	0.11% BGs	73.2% Decrease (0.30% Absolute)

Bode further explained that concerns over glucose control go well beyond patient safety, markedly impacting a hospital’s bottom line. He cited a recent study by Florida Hospital System (now known as AdventHealth Orlando): Financial Implications of Poor Glycemic Management & Improvement Strategies for Optimal Outcomes. The study observed a $10,405 greater cost of care (per stay) among insulin-managed patients who experienced severe hypoglycemia when compared to patients whose blood sugar remained in the normal range. Over a 12-month period from 2015 to 2016, the excess cost amounted to $7.7 million.

“Value-based reimbursement and bundled payments necessitate a solution to this problem,” said Bode. “This study exposed the extremely high cost of poor glucose control in hospitalized patients. Things need to change.”

Bode mentioned four FDA-cleared systems that offer computerized glucose management, but noted that Glytec’s eGMS^® is the only one capable of supporting diabetes therapies across both inpatient and outpatient settings of care, and Glytec is the only company with an evidence portfolio validating the safety and efficacy of solutions for intravenous insulin as well as subcutaneous basal-bolus insulin. Bode also described a head-to-head study⁶ between Glytec’s Glucommander IV solution and Monarch Medical Technologies’ EndoTool IV solution in which hypoglycemia <70 mg/dL was 58% lower with Glucommander IV vs. EndoTool IV (9.6% vs. 23.0% patients), hypoglycemia <40 mg/dL was 100% lower (0.0% vs. 1.1% patients) and duration on IV insulin was 45% lower (32.0 hours vs. 58.0 hours per patient).

“By normalizing, assessing and revising protocols and pathways for hyperglycemic management, we can ultimately achieve the goal of euglycemia without hypoglycemia,” said Bode, “and I fully envision that computerized systems will become the standard of care, because they serve the best interest of patients and providers, and they save money.”

________________________________
References:
1.	Safely Converting From Sliding Scale to Basal Bolus Insulin Across an Entire Medical Center via Implementation of the eGlycemic Management System. American Diabetes Association Scientific Sessions, June 2017.
2.	Comparison of Computer-Guided Versus Standard Insulin Infusion Regimens in Patients with Diabetic Ketoacidosis. American Association of Clinical Endocrinologists Annual Scientific & Clinical Congress, May 2016.
3.	Safely Converting an Entire Academic Medical Center From Sliding Scale to Basal Bolus Insulin via Implementation of the eGlycemic Management System. Journal of Diabetes Science and Technology, January 2018.
4.	Does Glycemic Control Using eGMS Reduce Readmission Rates for Hospitalized Patients Undergoing CABG? Annual Diabetes Technology Meeting, November 2016.
5.	Evaluating the Impact of eGMS^® Glucommander™ on Length of Stay, Hypoglycemia and Glucose Control in a Regional Medical Center. Annual Diabetes Technology Meeting, November 2018.
6.	A Comparison of Glycemic Outcomes for Two Computerized Insulin Infusion Algorithms in CV Surgery Patients. American Diabetes Association Scientific Sessions, June 2016.

About Glytec

Glytec is the pioneer of personalized digital therapeutics, enabling best practices for insulin optimization across the continuum of care. The company’s patented and FDA-cleared software-as-a-medical-device solutions improve the safety and health of people with diabetes in the hospital and at home. Glytec combines evidence-based decision support technologies with expert clinical services to make insulin a more effective medication option for the millions unable to achieve their treatment goals, leading to reductions in A1C, hypoglycemia and other complications as well as avoidable ED visits, hospitalizations, readmissions and drug waste. The company has offices in Waltham, Massachusetts and Greenville, South Carolina. For more information visit www.glytecsystems.com.